Combining PD1 inhibition with radiotherapy enhances anti-tumor responses in the CT26 colorectal mouse model

Sygnature Discovery presents new data demonstrating how PD1 inhibition, when combined with radiotherapy, improved anti-tumor responses in a preclinical CT26 colorectal model. This study highlights the value of combination strategies in preclinical immuno-oncology, with a focus on immune modulation and translational biomarker insights.

Study Highlights:

• Radiotherapy induces early DNA damage and immune signalling
• PD1 inhibition improves tumour control when combined with radiotherapy
• Immune cell profiling shows combination treatment drives immune activation
• Systemic immune activation supported by cytokine analysis

Advancing Preclinical Immuno-Oncology

This data supports the use of PD1 inhibition in combination with radiotherapy to drive improved therapeutic outcomes. The CT26 model provides a robust platform to evaluate immune checkpoint inhibitors and track changes in the tumor immune microenvironment, offering valuable insight for early-stage IO drug discovery.

Explore our Immuno-Oncology Expertise

Sygnature Discovery supports PD1 inhibition and checkpoint blockade research through our integrated preclinical immuno-oncology platform. Our capabilities include syngeneic tumor models, flow cytometry and translational biomarker analysis to guide combination IO strategies.